| Recruiting | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Re NCT07416890 | Zhejiang Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma NCT07405255 | Ruijin Hospital | Phase 2 |
| Recruiting | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous Syst NCT06607549 | University of Utah | Phase 1 |
| Recruiting | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL NCT05698147 | Tong Chen, MD | Phase 1 / Phase 2 |
| Recruiting | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lym NCT05625594 | City of Hope Medical Center | Phase 1 |
| Unknown | Decitabine and Anti-PD-1 in R/R DLBCL NCT05816746 | Chinese PLA General Hospital | Phase 2 |
| Completed | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma NCT06031194 | Ohio State University Comprehensive Cancer Center | — |
| Recruiting | Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Pa NCT05651178 | Hrain Biotechnology Co., Ltd. | EARLY_Phase 1 |
| Recruiting | Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma NCT05260619 | Seoul National University Bundang Hospital | Phase 2 |
| Recruiting | Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma NCT05209620 | Henan Cancer Hospital | Phase 2 |
| Unknown | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL NCT05054426 | Peking Union Medical College Hospital | Phase 3 |
| Active Not Recruiting | Acalabrutinib in CNSL NCT04906902 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Unknown | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance NCT04938297 | Henan Cancer Hospital | Phase 2 |
| Recruiting | DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489 | Miltenyi Biomedicine GmbH | Phase 2 |
| Active Not Recruiting | A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas NCT04548648 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Unknown | A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients NCT04516655 | Fudan University | Phase 2 |
| Recruiting | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Recruiting | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies NCT05011045 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphom NCT03964090 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma NCT03684980 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells NCT03375619 | Medical College of Wisconsin | — |
| Completed | Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity NCT03342586 | Memorial Sloan Kettering Cancer Center | — |
| Active Not Recruiting | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom NCT02952508 | Cellectar Biosciences, Inc. | Phase 2 |
| Unknown | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lym NCT02623010 | Rabin Medical Center | Phase 2 |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Unknown | Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular) NCT03859544 | Hospices Civils de Lyon | — |
| Terminated | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT02420795 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transpla NCT06625359 | Seoul National University Hospital | Phase 2 |
| Active Not Recruiting | MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway NCT03962127 | Norwegian University of Science and Technology | — |
| Completed | Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate NCT03690895 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Completed | Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System NCT01722305 | Mayo Clinic | Phase 1 |
| Recruiting | Secondary Central Nervous System Lymphoma Registry - Charité NCT05114330 | Charite University, Berlin, Germany | — |
| Completed | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma NCT01011920 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Completed | Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) NCT00916630 | Massachusetts General Hospital | Phase 1 |
| Completed | Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma NCT01458730 | University of Aarhus | Phase 2 |
| Completed | A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma NCT00221325 | University of California, San Francisco | Phase 1 |
| Unknown | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central N NCT00293475 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Completed | Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases NCT00103038 | OHSU Knight Cancer Institute | N/A |
| Completed | Study of Tissue Samples From Patients With Glioma or Other Brain Tumors NCT00967200 | University Hospital, Montpellier | — |
| Completed | Cognitive Functioning and Quality of Life in CNS Lymphoma NCT00581737 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) NCT00153530 | Charite University, Berlin, Germany | Phase 4 |